Octapharma AG: Indirect comparison data indicate that personalised prophylaxis with Nuwiq® may lead to fewer patients with haemophilia A having bleeds than with other recombinant factor VIII products

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

Octapharma-AG

More Like This

PR Newswire associated0

Octapharma to present clinical and scientific data that advances our understanding and treatment of bleeding disorders at the 17th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD), which takes place in Frankfurt, Germany, from February 6 - 9, 2024

PR Newswire associated0

Octapharma's continuing dedication to improving the lives of people with rare bleeding disorders to be showcased at ISTH 2024

NEJM publishes ALTUVOCT® phase 3 XTEND-Kids results highlighting treatment potential for children with severe haemophilia A

European Commission grants Sobi® Marketing Authorisation for ALTUVOCT™ for treatment of haemophilia A

Sobi to showcase new data across haemophilia portfolio at ISTH 2026

PR Newswire associated0

Denecimig (Mim8) significantly reduced annualized bleeding rate in people with hemophilia A, regardless of inhibitor status, in phase 3 data published in NEJM

PR Newswire associated0

Novo Nordisk submits Biologics License Application (BLA) to FDA for Mim8; an investigational, prophylaxis treatment for people living with hemophilia A with or without inhibitors

PR Newswire associated0

Novo Nordisk's denecimig (Mim8) demonstrated positive results in long term safety and efficacy in phase 3 hemophilia A FRONTIER extension study at ISTH 2026